{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-093930","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.746039+00:00","generated_at":"2026-05-17T05:16:38.568404+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INmune Bio submits Phase 2 MINDFuL manuscript; highlights subgroup benefit and no ARIA","bullets":["Phase 2 MINDFuL trial of XPro1595 missed primary endpoint overall but showed positive trends in ADi subgroup with high inflammatory burden.","No amyloid-related imaging abnormalities (ARIA) observed, even in high-risk patients (APOE4 carriers, anticoagulants, microbleeds).","Manuscript submitted to npj Dementia (Nature Portfolio); preprint available on medRxiv.","Expects FDA feedback for end-of-Phase 2 discussions in Q1 2026.","XPro1595 selectively neutralizes soluble TNF, targeting neuroinflammation in precision medicine approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-093930","json":"https://secwatch.observer/filing/0001213900-25-093930.json","markdown":"https://secwatch.observer/filing/0001213900-25-093930.md","text":"https://secwatch.observer/filing/0001213900-25-093930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/0001213900-25-093930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/ea0258531-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:16:38.568404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}